Seeking Alpha

MannKind announces Ad Com date, shares stumble

  • MannKind Pharmaceuticals (MNKD) trades lower by 11% in premarket action.
  • The company says an Afrezza Ad Com has been tentatively scheduled for April 1.
  • Also not helping matters is The Street's Adam Feuerstein, who had the following to say today about the inhaled insulin product's chances for approval: "The results from the two phase 3 studies announced this summer were barely passable [and] we still don't know, exactly, how the current 'Dreamboat' inhaler performed relative to the older Medtone inhaler."
  • "None of the Afrezza data have been presented at a medical meeting or published," Feuerstein notes, adding that while he "absolutely" could be wrong about the drug's chances, "there's certainly precedent for an Afrezza rejection. Two, actually."
Comments (14)
  • Adam F. at his best. How does this guy still have a job?
    10 Jan, 09:27 AM Reply Like
  • They probably don't pay him over at The Street. He makes a percentage from the shorts...


    Seriously people, read his articles on Mannkind before selling. He doesn't even do his own research just quotes someone else and brings up old irrelevant information.


    Regarding the device comparison. Mannkind did exactly what the FDA asked for (in the last clinical trials)...and they met the primary end points. But, you the Mannkind investor should already know this...


    If you didn't, you shouldn't be investing in MNKD. And, if you follow Adams advice on anything (without doing your own research) you should not be in stocks..seriously buy an ETF.


    FYI: the real reason for the pullback was because the stock was overextended technically. I expect the MNKD to be between $8 to $10 by April 1st.


    Long MNKD


    This is a message to the general public not a specific comment to a post.
    10 Jan, 10:35 AM Reply Like
  • Feuerstein is known to short almost all biotech stocks. He was right sometimes, like $ZLCS. But most of his calls were wrong, and yet he makes a fortune from panic selling almost every time he says something. Don't believe everything he says. We should do our own DD, and make volatility our friend.
    10 Jan, 10:41 AM Reply Like
  • By making churning up circumstances to favor the Shorts .....
    10 Jan, 09:54 AM Reply Like
  • In other words-1+1 = 3.... Most of the time . Except sometimes it equals 2 . I could be wrong though. Somebody once told me the answer was 4. Ya' know?
    10 Jan, 09:58 AM Reply Like
  • Retail investor. Does MNKD have a partner for Afrezza?
    10 Jan, 10:29 AM Reply Like
  • No, not yet. Partnering before approval of the product would result in a lower bargaining chip and a lower % of revenue.
    10 Jan, 10:45 AM Reply Like
  • This guy still is not giving the facts. the rejection by the FDA was not because of Afreeza. It was because of the switch to a new inhaler. Also even if it proves equal to inject-able in end. I am sure a huge majority of people would switch the the inhaled insulin. Did he even read the circumstances under which it was rejected the first time? No because if he did it appears like some one thought it was going to be approved and thus brought a lot of stock. Only to have it not approved by the FDA. But I guess the guy would not have a job if he did not have to say something to go against what is going to be a huge money maker in the insulin arena. One more thing the guy behind inhaled insulin has had way to many the insulin pump, cgm and etc.
    10 Jan, 10:30 AM Reply Like
  • Yeah, Adam F is not credible imo. I don't listen to him. Notice how mnkd is still up about 4% over the past 2 days... He puts this out right after a big day... perfect timing...


    notice hes says results are barely passable.... which if you know something about statistics doesn't matter. If it passes its significant, there is no barely.


    Also, its a spec biotech.... its almost always 50/50 chance. the point is MNKD potential sales and market cap is huge, and thereby worth the bet. Going short maxes at 100% profit, going long maxes at infinite profit.
    10 Jan, 03:22 PM Reply Like
  • Shame on SA reporting such gross and obviously biased comment from an irrelevant short.I'd like to read about facts and real news, not about the trash opinion of a short that does not even understand the aim of the last Affinity 1 and 2 studies.. At this point, why didn't you SA even publish the funny last part about supposed "persistent cough"? You even linked the page as if it's something worth a glance.. please, be more objective for the sake of your professionalism.
    10 Jan, 04:44 PM Reply Like
  • AF does not have much credibility. He seems to provide poorly argumented opinions. To me, a positive FDA decision would be the last nail. I would then completely ignore his positions.
    When comparing SA factual articles and AF's 30 seconds claims, I must say AF does not come out on top.
    12 Jan, 09:13 PM Reply Like
  • I'm fairly new at this game, however the action of the stock today was fairly predictable. There was a gap left between the close of 1/8/14 close $5.985 and the strong open of 1/9/14 $6.02. From what I've learned, most stocks close their gaps. Thank God today at the close they finally closed that gap. It took 4 attempts. Put up a traders chart 10/10 and you will see I had a long day waiting for that close. Let's see what Monday brings.I live in NH and I hope it's not snow. It's fun reading your comments, I hope you all have a good weekend.


    12 Jan, 09:24 PM Reply Like
  • Gaps have a way of filling sometimes, but this is not always the case. Saying that MNKD's action was "fairly predictable" is far from the truth. If it were that easy everyone would be rich. Stocks continue higher never filling small, and even large, gaps everyday.


    With that said, trading on gaps is better than trading on nothing. Good luck
    12 Jan, 10:01 PM Reply Like
  • During today's conference call, Al Mann, apparently taking aim at Feuerstein's negative remark that all Affrezza test data has yet to be released, explained why as follows:


    "After the advisory committee meeting, the next major occasion to talk in detail about the clinical potential, which today is exclusive, only with AFREZZA, will be the annual meeting of the American Diabetes Association.


    That ADA session will be the first scientific meeting at which we will publicly present the full data from our recent Phase III studies, MKC-171 and 175. I know some investors had wanted earlier disclosure of the complete results of those pivotal trials, but in order to reserve the opportunity to present novel results at a major scientific meeting and to publish the studies in a peer reviewed journal, it is necessary that we comply with the editorial policies of those organizations, which do not accept for presentation or publication any previously disclosed research findings."
    18 Feb, 09:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)